vs

Side-by-side financial comparison of TORO CO (TTC) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

TORO CO is the larger business by last-quarter revenue ($1.1B vs $961.0M, roughly 1.2× DENTSPLY SIRONA Inc.). TORO CO runs the higher net margin — 4.7% vs -15.2%, a 19.9% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -2.2%). TORO CO produced more free cash flow last quarter ($207.2M vs $60.0M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -8.1%).

The Toro Company is an American company based in the Minneapolis suburb of Bloomington, Minnesota, that designs, manufactures, and markets lawn mowers, snow blowers, and irrigation system supplies for commercial and residential, agricultural, and public sector uses.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

TTC vs XRAY — Head-to-Head

Bigger by revenue
TTC
TTC
1.2× larger
TTC
$1.1B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+8.4% gap
XRAY
6.2%
-2.2%
TTC
Higher net margin
TTC
TTC
19.9% more per $
TTC
4.7%
-15.2%
XRAY
More free cash flow
TTC
TTC
$147.2M more FCF
TTC
$207.2M
$60.0M
XRAY
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-8.1%
TTC

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
TTC
TTC
XRAY
XRAY
Revenue
$1.1B
$961.0M
Net Profit
$53.5M
$-146.0M
Gross Margin
33.7%
46.1%
Operating Margin
5.7%
-14.5%
Net Margin
4.7%
-15.2%
Revenue YoY
-2.2%
6.2%
Net Profit YoY
-55.2%
66.0%
EPS (diluted)
$0.54
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TTC
TTC
XRAY
XRAY
Q4 25
$961.0M
Q3 25
$1.1B
$904.0M
Q2 25
$1.3B
$936.0M
Q1 25
$995.0M
$879.0M
Q4 24
$905.0M
Q3 24
$1.2B
$951.0M
Q2 24
$1.3B
$984.0M
Q1 24
$1.0B
$953.0M
Net Profit
TTC
TTC
XRAY
XRAY
Q4 25
$-146.0M
Q3 25
$53.5M
$-427.0M
Q2 25
$136.8M
$-45.0M
Q1 25
$52.8M
$20.0M
Q4 24
$-430.0M
Q3 24
$119.3M
$-494.0M
Q2 24
$144.8M
$-4.0M
Q1 24
$64.9M
$18.0M
Gross Margin
TTC
TTC
XRAY
XRAY
Q4 25
46.1%
Q3 25
33.7%
48.8%
Q2 25
33.1%
52.4%
Q1 25
33.7%
53.0%
Q4 24
49.3%
Q3 24
34.8%
52.1%
Q2 24
33.6%
51.9%
Q1 24
34.4%
53.1%
Operating Margin
TTC
TTC
XRAY
XRAY
Q4 25
-14.5%
Q3 25
5.7%
-24.1%
Q2 25
13.3%
-13.7%
Q1 25
7.8%
7.2%
Q4 24
-56.2%
Q3 24
12.8%
-48.6%
Q2 24
13.9%
5.1%
Q1 24
8.8%
4.4%
Net Margin
TTC
TTC
XRAY
XRAY
Q4 25
-15.2%
Q3 25
4.7%
-47.2%
Q2 25
10.4%
-4.8%
Q1 25
5.3%
2.3%
Q4 24
-47.5%
Q3 24
10.3%
-51.9%
Q2 24
10.7%
-0.4%
Q1 24
6.5%
1.9%
EPS (diluted)
TTC
TTC
XRAY
XRAY
Q4 25
$-0.74
Q3 25
$0.54
$-2.14
Q2 25
$1.37
$-0.22
Q1 25
$0.52
$0.10
Q4 24
$-2.09
Q3 24
$1.14
$-2.46
Q2 24
$1.38
$-0.02
Q1 24
$0.62
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TTC
TTC
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$326.0M
Total DebtLower is stronger
$1.0B
$2.3B
Stockholders' EquityBook value
$1.4B
$1.3B
Total Assets
$3.5B
$5.4B
Debt / EquityLower = less leverage
0.73×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TTC
TTC
XRAY
XRAY
Q4 25
$326.0M
Q3 25
$363.0M
Q2 25
$359.0M
Q1 25
$398.0M
Q4 24
$272.0M
Q3 24
$296.0M
Q2 24
$279.0M
Q1 24
$291.0M
Total Debt
TTC
TTC
XRAY
XRAY
Q4 25
$2.3B
Q3 25
$1.0B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.7B
Q3 24
$991.9M
Q2 24
$1.0B
Q1 24
$1.2B
Stockholders' Equity
TTC
TTC
XRAY
XRAY
Q4 25
$1.3B
Q3 25
$1.4B
$1.5B
Q2 25
$1.5B
$2.0B
Q1 25
$1.5B
$2.0B
Q4 24
$1.9B
Q3 24
$1.6B
$2.5B
Q2 24
$1.7B
$3.1B
Q1 24
$1.5B
$3.3B
Total Assets
TTC
TTC
XRAY
XRAY
Q4 25
$5.4B
Q3 25
$3.5B
$5.7B
Q2 25
$3.8B
$6.1B
Q1 25
$3.7B
$6.0B
Q4 24
$5.8B
Q3 24
$3.7B
$6.6B
Q2 24
$3.9B
$6.9B
Q1 24
$3.8B
$7.1B
Debt / Equity
TTC
TTC
XRAY
XRAY
Q4 25
1.70×
Q3 25
0.73×
Q2 25
0.74×
Q1 25
0.75×
Q4 24
0.90×
Q3 24
0.61×
Q2 24
0.62×
Q1 24
0.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TTC
TTC
XRAY
XRAY
Operating Cash FlowLast quarter
$225.8M
$101.0M
Free Cash FlowOCF − Capex
$207.2M
$60.0M
FCF MarginFCF / Revenue
18.3%
6.2%
Capex IntensityCapex / Revenue
1.6%
4.3%
Cash ConversionOCF / Net Profit
4.22×
TTM Free Cash FlowTrailing 4 quarters
$462.5M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TTC
TTC
XRAY
XRAY
Q4 25
$101.0M
Q3 25
$225.8M
$79.0M
Q2 25
$171.7M
$48.0M
Q1 25
$-48.6M
$7.0M
Q4 24
$87.0M
Q3 24
$194.7M
$141.0M
Q2 24
$227.3M
$208.0M
Q1 24
$-92.2M
$25.0M
Free Cash Flow
TTC
TTC
XRAY
XRAY
Q4 25
$60.0M
Q3 25
$207.2M
$40.0M
Q2 25
$152.4M
$16.0M
Q1 25
$-67.7M
$-12.0M
Q4 24
$36.0M
Q3 24
$170.6M
$98.0M
Q2 24
$206.9M
$156.0M
Q1 24
$-111.3M
$-9.0M
FCF Margin
TTC
TTC
XRAY
XRAY
Q4 25
6.2%
Q3 25
18.3%
4.4%
Q2 25
11.6%
1.7%
Q1 25
-6.8%
-1.4%
Q4 24
4.0%
Q3 24
14.7%
10.3%
Q2 24
15.3%
15.9%
Q1 24
-11.1%
-0.9%
Capex Intensity
TTC
TTC
XRAY
XRAY
Q4 25
4.3%
Q3 25
1.6%
4.3%
Q2 25
1.5%
3.4%
Q1 25
1.9%
2.2%
Q4 24
5.6%
Q3 24
2.1%
4.5%
Q2 24
1.5%
5.3%
Q1 24
1.9%
3.6%
Cash Conversion
TTC
TTC
XRAY
XRAY
Q4 25
Q3 25
4.22×
Q2 25
1.26×
Q1 25
-0.92×
0.35×
Q4 24
Q3 24
1.63×
Q2 24
1.57×
Q1 24
-1.42×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TTC
TTC

Equipment Products And Services$815.7M72%
Residential Segment$192.8M17%
Irrigation$115.1M10%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons